For health technology assessment (HTA) agencies, cancer drugs provide a special set of challenges and level of complexity in their reimbursement evaluations. Measuring surrogate endpoints, valuing high-cost combination therapies, and keeping up with innovations like immunotherapies are all nuanced examples that are especially challenging in oncology. Watch here. (Source: Context Matters, 2016)
You are here: / / Is Your Oncology Drug HTA-Ready?